



News Release

Cougar Biotechnology to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference

Los Angeles, CA, April 5, 2007 – Cougar Biotechnology, Inc. (OTCBB: CGRB) today announced that Alan H. Auerbach, Chief Executive Officer and President of Cougar, will be presenting at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference on Wednesday, April 11, at 3:40 p.m. EDT at the Millennium Broadway Hotel in New York City. Mr. Auerbach will provide a company overview and update on the status of Cougar's current clinical development programs.

Interested investors may access a live audio webcast and accompanying slide presentation by visiting the Investor Relations section of the Company's Web site at www.cougarbiotechnology.com. The presentation will be archived on the Web site and available for 30 days.

About Cougar Biotechnology

Cougar Biotechnology, Inc. is a Los Angeles-based biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar's oncology portfolio includes CB7630, a targeted inhibitor of the 17-alpha hydroxylase/c17,20 lyase enzyme, which is currently being tested in Phase II clinical trials in prostate cancer; CB3304, an inhibitor of microtubule dynamics, which is currently in a Phase I trial in hematological malignancies and CB1089, an analog of vitamin D, which has been clinically tested in a number of solid tumor types.

Further information about Cougar Biotechnology can be found at www.cougarbiotechnology.com.

This press release contains forward-looking statements that involve risks and uncertainties that could cause Cougar's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that the development of CB7630 or Cougar's other product candidates will ever be successfully completed, or that Cougar will ever receive the regulatory approvals necessary to commercialize CB7630 or Cougar's other product candidates. Other risks that may affect forward-looking information contained in this press release include the risk that the results of clinical trials may not support Cougar's claims, Cougar's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the Company's Current Annual Report on Form 10-KSB filed with the Securities and Exchange Commission on April 2, 2007. Cougar assumes no obligation to update these statements, except as required by law.

Contacts:

Cougar Biotechnology, Inc. -- +1-310-943-8040
Alan H. Auerbach, Chief Executive Officer and President
ahauerbach@cougarbiotechnology.com
Mariann Ohanesian, Director of Investor Relations
mohanesian@cougarbiotechnology.com

Noonan Russo
David Schull, +1-212-845-4271
David.schull@eurorsg.com
Andreas Marathovouniotis, +1-212-845-4253
Andreas.marathis@eurorsg.com